尿路上皮悪性腫瘍における抗癌剤感受性試験- human tumor clonogenic assayを中心として -

概要

論文の詳細を見る
泌尿***悪性腫瘍127例(腎盂尿管移行上皮癌21例,膀胱移行上皮癌33例,腎細胞癌61例,睾丸腫瘍8例,およびWilms腫瘍4例)の手術材料および一部生検により得られた材料を用いて,human tumor clonogenic assay (HTC assay)およびnovel dye exclusion method (NDE assay)による抗癌剤感受性試験を行なった.さらにHTC assayの感受性結果とNDE assayのそれとを比較した.HTC assayは85例に施行され,コロニー形成率は腎盂尿管癌にて0.09±0.05%,膀胱移行上皮癌にて0.05±0.04%,および腎細胞癌にて0.05±0.03%であった.感受性評価可能例は28例(33%)であり,その内訳は腎盂尿管移行上皮癌にてはADRに対して4例中1例が,CDDPに対して6例中1例が,CQに対して5例中1例が感受性を示した.また膀胱移行上皮癌においてはADRに対して9例中2例が,CDDPに対して10例中3例が,CQに対して10例中3例が感受性を示した.腎細胞癌にてはADRに対して9例中2例が,VLBに対して11例中4例が感受性を示した.いずれの癌においても抗癌剤に対して感受性を示す症例は20-30%と低率であった.NDE assayは63例に施行され,40例(64%)に抗癌剤感受性試が可能であった.同時に同じ濃度の抗癌剤にて施行可能であった11症例,31感受性試験におけるHTC assayとNDE assayでは,両assayにて感受性ありと判定された感受性結果は31試験中0,一方,感受性なしと判定された結果は31試験中24試験(77%)に認められたA soft agar colony formation assay, so called human tumor clonogenic assay (HTC assay) similar to that originally described by Salmon and colleagues, was utilized to measure the sensitivity of a total of 85 urologic malignancies including 36 urothelial cell carcinomas, 41 renal cell carcinomas, 5 testicular tumors, and 3 Wilms' tumors to anticancer drugs. In addition, the results obtained were compared with those of a novel dye exclusion method (NDE assay) described by Weisenthal and colleagues. The NDE assay was utilized to measure the sensitivity of a total of 63 urologic malignancies including 28 urothelial cell carcinomas, 25 renal cell carcinomas, 6 testicular tumors, and 4 Wilms' tumors to anticancer agents. In both assay series, the concentration of anticancer drugs tested was approximately one tenth of the maximum serum level achievable after single bolus injection. The colony forming rate inhibition of 70% or more in the HTC assay and the cell survival rate of 30% or less in the NDE assay were defined as "sensitive." Sixteen of the 36 urothelial cell carcinomas, 11 of the 41 renal cell carcinomas, and 1 of the 5 testicular tumors had both more than 30 colonies grown in control plates and enough cells in the specimens to provide at least one drug sensitivity testing. In urothelial cell carcinomas, 3 out of 13 tumors were "sensitive" to adriamycin, 3 out of 16 to cis-platinum, and 4 out of 15 to carboquone. In renal cell carcinomas, 2 out of 9 tumors were "sensitive" to adriamycin, 4 out of 11 to vinblastine, and none of 4 to Interferon alpha.(ABSTRACT TRUNCATED AT 250 WORDS)

著者

天野俊康
金沢大

尿路上皮悪性腫瘍における抗癌剤感受性試験- human tumor clonogenic assayを中心として -

スポンサーリンク

概要

著者

関連論文

スポンサーリンク